Literature DB >> 21181508

In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation.

Sandra Grbic1, Jelena Parojcic, Svetlana Ibric, Zorica Djuric.   

Abstract

The aim of this study was to develop a drug-specific absorption model for gliclazide (GLK) using mechanistic gastrointestinal simulation technology (GIST) implemented in GastroPlus(TM) software package. A range of experimentally determined, in silico predicted or literature data were used as input parameters. Experimentally determined pH-solubility profile was used for all simulations. The human jejunum effective permeability (P (eff)) value was estimated on the basis of in vitro measured Caco-2 permeability (literature data). The required PK inputs were taken from the literature. The results of the simulations were compared with actual clinical data and revealed that the GIST-model gave accurate prediction of gliclazide oral absorption. The generated absorption model provided the target in vivo dissolution profile for in vitro-in vivo correlation and identification of biorelevant dissolution specification for GLK immediate-release (IR) tablets. A set of virtual in vitro data was used for correlation purposes. The obtained results suggest that dissolution specification of more than 85% GLK dissolved in 60 min may be considered as "biorelevant" dissolution acceptance criteria for GLK IR tablets.
© 2010 American Association of Pharmaceutical Scientists

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181508      PMCID: PMC3066385          DOI: 10.1208/s12249-010-9573-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

1.  Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with beta-cyclodextrin.

Authors:  Y Ozkan; T Atay; N Dikmen; A Işimer; H Y Aboul-Enein
Journal:  Pharm Acta Helv       Date:  2000-04

Review 2.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

Authors:  B Agoram; W S Woltosz; M B Bolger
Journal:  Adv Drug Deliv Rev       Date:  2001-10-01       Impact factor: 15.470

3.  Biopharmaceutics classification system: the scientific basis for biowaiver extensions.

Authors:  Lawrence X Yu; Gordon L Amidon; James E Polli; Hong Zhao; Mehul U Mehta; Dale P Conner; Vinod P Shah; Lawrence J Lesko; Mei-Ling Chen; Vincent H L Lee; Ajaz S Hussain
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

4.  Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide.

Authors:  K Kobayashi; M Kimura; T Sakoguchi; Y Kitani; M Hata; A Matsuoka
Journal:  J Pharmacobiodyn       Date:  1981-06

5.  Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.

Authors:  P Delrat; M Paraire; R Jochemsen
Journal:  Biopharm Drug Dispos       Date:  2002-05       Impact factor: 1.627

6.  Development of predictive pharmacokinetic simulation models for drug discovery.

Authors:  D A Norris; G D Leesman; P J Sinko; G M Grass
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

7.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

8.  Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide & Diamicron)--in healthy human volunteers.

Authors:  Naji Najib; Nasir Idkaidek; M Beshtawi; Mohammed Bader; Isra' Admour; S Mahmood Alam; Q Zaman; Ruwayda Dham
Journal:  Biopharm Drug Dispos       Date:  2002-07       Impact factor: 1.627

9.  Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model.

Authors:  Jun-ichi Yokoe; Norio Iwasaki; Shunji Haruta; Keitaro Kadono; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  J Control Release       Date:  2003-01-17       Impact factor: 9.776

10.  Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Paul J Fawcett; Svetlana Golocorbin-Kon; Ivan Mikov; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

View more
  6 in total

1.  In vitro-in vivo correlation of efavirenz tablets using GastroPlus®.

Authors:  Thiago da Silva Honório; Eduardo Costa Pinto; Helvécio Vinicius A Rocha; Valeria Sant'Anna Dantas Esteves; Tereza Cristina dos Santos; Helena Carla Rangel Castro; Carlos Rangel Rodrigues; Valeria Pereira de Sousa; Lucio Mendes Cabral
Journal:  AAPS PharmSciTech       Date:  2013-08-14       Impact factor: 3.246

2.  Formulation, Pharmacokinetics evaluation, and IVIVC Assessment of Gliclazide Multiparticulates in Rat Model.

Authors:  Ahmed A El-Ashmawy; Aya R Abdou; Nesrin F Taha; Ebtesam W Elsayed; Khaled M Mahmoud; Laila H Emara
Journal:  AAPS PharmSciTech       Date:  2021-04-30       Impact factor: 3.246

3.  Controlled porosity solubility modulated osmotic pump tablets of gliclazide.

Authors:  Arti Banerjee; P R P Verma; Subhash Gore
Journal:  AAPS PharmSciTech       Date:  2014-11-07       Impact factor: 3.246

4.  Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies.

Authors:  Lidiane M Monteiro; Viviane F Lione; Flavia A do Carmo; Lilian H do Amaral; Julianna H da Silva; Luiz E Nasciutti; Carlos R Rodrigues; Helena C Castro; Valeria P de Sousa; Lucio M Cabral
Journal:  Int J Nanomedicine       Date:  2012-09-28

5.  Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study.

Authors:  Alaa Mohamed Nazief; Passainte Saber Hassaan; Hoda Mahmoud Khalifa; Magda Samir Sokar; Amal Hassan El-Kamel
Journal:  Int J Nanomedicine       Date:  2020-02-18

6.  Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype.

Authors:  Tanja Dujic; Sandra Cvijic; Amar Elezovic; Tamer Bego; Selma Imamovic Kadric; Maja Malenica; Alisa Elezovic; Ewan R Pearson; Aida Kulo
Journal:  J Pers Med       Date:  2021-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.